Investment analysis, share recommendations, and market insights.
Is it time to relook at the healthcare sector? Here are 5 healthcare stocks that could be on the way up. But if you don't want to 'bet' on one company, possibly an ETF like the well-named DRUG, could be an option.
In a month where the US S&P 500 added 10.5%, the Aussie share market clawed higher in April to record a gain of just 2.2%. Our model portfolios, which are marginally overweight resources, continued to outperform.
Raymond Chan, Private Adviser & Head of Asian Desk at Morgans, explains why Morgans regards ResMed (RMD) as a BUY.
Here are three stocks, two with world-leading proprietary software and one with a growing specialisation in providing its clients with the capability and capacity to make AI viable for them. Each one looks to have substantial scope to rise from current prices.
For the week ending Friday 1 May 2026, FNArena recorded nine upgrades and 10 downgrades from the seven brokers monitored daily across ASX-listed companies.
Switzer TV aired its 4 May 2026 edition on the eve of the RBA's May rate decision, with four expert guests joining Peter Switzer to discuss the macro setup, where the charts are pointing, and which stocks are positioned best heading into a potential third rate hike for 2026.
Here are five companies that brought out strong reports for the March 2026 quarter; all of which appear to offer good value at current prices.
Here's a realistic take on what smart investors are doing stocks-wise right now.
Michael Gable, Managing Director of Fairmont Equities, explains why Arafura Rare Earths (ARU) is potentially a higher risk/reward way for investors to gain exposure to the rare earth market.
Raymond Chan, private client adviser and head of Asian Desk, notes that Morgans has a BUY rating on Newmont Corporation (NEM).
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.